JP2020525425A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020525425A5 JP2020525425A5 JP2019570406A JP2019570406A JP2020525425A5 JP 2020525425 A5 JP2020525425 A5 JP 2020525425A5 JP 2019570406 A JP2019570406 A JP 2019570406A JP 2019570406 A JP2019570406 A JP 2019570406A JP 2020525425 A5 JP2020525425 A5 JP 2020525425A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- garcinol
- endoplasmic reticulum
- effective concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DTTONLKLWRTCAB-UDFURZHRSA-N (1s,3e,5r,7r)-3-[(3,4-dihydroxyphenyl)-hydroxymethylidene]-6,6-dimethyl-5,7-bis(3-methylbut-2-enyl)-1-[(2s)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]bicyclo[3.3.1]nonane-2,4,9-trione Chemical compound O=C([C@@]1(C(C)(C)[C@H](CC=C(C)C)C[C@](C2=O)(C1=O)C[C@H](CC=C(C)C)C(C)=C)CC=C(C)C)\C2=C(\O)C1=CC=C(O)C(O)=C1 DTTONLKLWRTCAB-UDFURZHRSA-N 0.000 claims description 14
- QDKLRKZQSOQWJQ-JGWHSXGBSA-N Garcinol Natural products O=C([C@@]1(C(C)(C)[C@@H](CC=C(C)C)C[C@](C=2O)(C1=O)C[C@H](CC=C(C)C)C(C)=C)CC=C(C)C)C=2C(=O)C1=CC=C(O)C(O)=C1 QDKLRKZQSOQWJQ-JGWHSXGBSA-N 0.000 claims description 14
- LMFLOMBYUXRHIL-UHFFFAOYSA-N garcifuran-A Natural products COC1=C(O)C(OC)=CC(C=2C(=C3C=COC3=CC=2)O)=C1 LMFLOMBYUXRHIL-UHFFFAOYSA-N 0.000 claims description 14
- GRBCIRZXESZBGJ-UHFFFAOYSA-N guttiferone F Natural products CC(=CCCC(C(=C)C)C12CC(CC=C(C)C)C(C)(C)C(CC=C(C)C)(C(=O)C(=C1O)C(=O)c3ccc(O)c(O)c3)C2=O)C GRBCIRZXESZBGJ-UHFFFAOYSA-N 0.000 claims description 14
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 8
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 8
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 8
- 231100000419 toxicity Toxicity 0.000 claims description 8
- 230000001988 toxicity Effects 0.000 claims description 8
- -1 gummy Substances 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 238000009825 accumulation Methods 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 206010016262 Fatty liver alcoholic Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 4
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 208000010706 fatty liver disease Diseases 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 201000001421 hyperglycemia Diseases 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 claims description 2
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 claims description 2
- 101150112743 HSPA5 gene Proteins 0.000 claims description 2
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 claims description 2
- 101150028578 grp78 gene Proteins 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000013589 supplement Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523592P | 2017-06-22 | 2017-06-22 | |
| US62/523,592 | 2017-06-22 | ||
| PCT/US2018/038950 WO2018237243A1 (en) | 2017-06-22 | 2018-06-22 | Garcinol compositions for therapeutic management of endoplasmic reticulum stress |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020525425A JP2020525425A (ja) | 2020-08-27 |
| JP2020525425A5 true JP2020525425A5 (enExample) | 2021-06-10 |
Family
ID=64691689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570406A Pending JP2020525425A (ja) | 2017-06-22 | 2018-06-22 | 小胞体ストレスの治療管理のためのガルシノール組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180369166A1 (enExample) |
| EP (1) | EP3614846A4 (enExample) |
| JP (1) | JP2020525425A (enExample) |
| KR (1) | KR20200011492A (enExample) |
| AU (1) | AU2018290320A1 (enExample) |
| CA (1) | CA3065332A1 (enExample) |
| WO (1) | WO2018237243A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110317776A (zh) * | 2019-07-31 | 2019-10-11 | 遵义医学院附属医院 | 一种内质网应激细胞模型的建立方法 |
| CN111454350B (zh) * | 2020-06-01 | 2020-12-29 | 广东丸美生物技术股份有限公司 | 一种重组纤连蛋白突变体及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11139965A (ja) * | 1997-11-06 | 1999-05-25 | Kikkoman Corp | 抗腫瘍薬 |
| JP2000044468A (ja) * | 1998-07-29 | 2000-02-15 | Kikkoman Corp | リパーゼ阻害剤及び抗肥満剤又は高脂血症抑制剤 |
| IN2003CH00929A (enExample) * | 2003-11-13 | 2008-10-06 | ||
| GB0710976D0 (en) * | 2007-06-07 | 2007-07-18 | Bioalvo | Am Screening method |
| EP2346522A4 (en) * | 2008-09-23 | 2012-02-29 | Bach Pharma Inc | PROCESS FOR MODULATING PROTEIN HOMEOSTASIS, METABOLISM SYNDROME, HEAVY METAL POISONING AND NRF2 TRANSCRIPTION FACTORS |
| US20120207744A1 (en) * | 2009-03-19 | 2012-08-16 | Mendlein John D | Reprogramming compositions and methods of using the same |
| CN102573500A (zh) * | 2009-08-06 | 2012-07-11 | 纽拉尔图斯制药公司 | 巨噬细胞相关疾病的治疗 |
| JP5888637B2 (ja) * | 2010-06-14 | 2016-03-22 | 日産化学工業株式会社 | 造血幹細胞の製造方法 |
| KR101654832B1 (ko) * | 2010-12-09 | 2016-09-06 | 인두스 바이오텍 프라이빗 리미티드 | 가르시놀, 사이클로덱스트린의 착물 및 이의 제조방법 |
| PT2658374E (pt) * | 2010-12-30 | 2016-03-04 | Majeed Muhammed | Atividade hepatoprotetora do garcinol |
| US8329743B2 (en) * | 2011-01-10 | 2012-12-11 | Sami Labs Limited | Compositions and its use in treating obesity or inducing weight loss |
| WO2015049553A1 (en) * | 2013-10-03 | 2015-04-09 | Delhi Institute Of Pharmaceutical Sciences And Research | Effect of garcinol in delaying the progression of diabetic nephropathy |
-
2018
- 2018-06-22 US US16/015,503 patent/US20180369166A1/en not_active Abandoned
- 2018-06-22 EP EP18821067.8A patent/EP3614846A4/en not_active Withdrawn
- 2018-06-22 CA CA3065332A patent/CA3065332A1/en active Pending
- 2018-06-22 AU AU2018290320A patent/AU2018290320A1/en not_active Abandoned
- 2018-06-22 KR KR1020197038408A patent/KR20200011492A/ko not_active Ceased
- 2018-06-22 JP JP2019570406A patent/JP2020525425A/ja active Pending
- 2018-06-22 WO PCT/US2018/038950 patent/WO2018237243A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250375415A1 (en) | Enhancing autophagy or increasing longevity by administration of urolithins | |
| Mikkelsen et al. | Vitamin B1, B2, B3, B5, and B6 and the immune system | |
| US6184248B1 (en) | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases | |
| EP3569250B1 (en) | Pemafibrate in combination with a sglt2 inhibitor for the prophylactic or therapeutic treatment of liver diseases nonalcoholic fatty liver disease | |
| JP2022101529A (ja) | アレルギー疾患の治療方法 | |
| JP2020525425A5 (enExample) | ||
| CN107050016B (zh) | 原苏木素a的医药用途 | |
| Qi et al. | Alpinia oxyphylla–Schisandra chinensis Herb Pair Alleviates Amyloid-β Induced Cognitive Deficits via PI3K/Akt/Gsk-3β/CREB Pathway | |
| JP5936707B2 (ja) | インターフェロンおよびアンドログラホリドを用いた多発性硬化症のための併用療法 | |
| EP4051248A1 (en) | The cholesterol-synthesis intermediates for treatment demyelinating disorders | |
| CN115778944A (zh) | 蛇床子素在制备改善或治疗认知功能障碍的药物中的用途 | |
| WO2022186170A1 (ja) | 脳血管障害を予防または治療するための組成物 | |
| CN117379414A (zh) | 盐酸决奈达隆在制备治疗非酒精性脂肪性肝病和胆汁淤积性肝病的药物中的应用 | |
| US20180369166A1 (en) | Garcinol compositions for therapeutic management of endoplasmic reticulum stress | |
| US20200093782A1 (en) | Ariants of 2-[6-(4-chlorophenoxy)hexyl]-oxirane-2-carboxylic acid for use in the treatment, prevention and/or amelioration of brain diseases | |
| KR102346790B1 (ko) | 콜히친과 메트포르민을 유효성분으로 하는 항비만 치료제 | |
| CN112076187B (zh) | 安卓锭在制备用于预防或治疗非酒精性脂肪肝的药物中的用途 | |
| Zheng et al. | Sesaminol Ameliorates Age-Related Cognitive Decline and Neuroinflammation by Modulating Microglial Polarization and Enhancing Aβ Phagocytosis in Mice | |
| CN109908152B (zh) | 一种防控对乙酰氨基酚所致肝损伤的药物及其应用 | |
| CN111973597A (zh) | Abemaciclib在制备治疗NAFLD的药物中的应用 | |
| CN109700965B (zh) | 一种减肥降脂的组合物及其制备方法与用途 | |
| US9512168B2 (en) | Compound, composition and method for treating and/or ameoliorating kidney disease |